Clinical trials: Rituximab, completed
Lymphoma, Non-Hodgkin
Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the second line therapy of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma
- Trial name
- NCT02072967
- Testing
- Ribomustin, rituximab
- Where
- 35 sites in Russia
- Volunteers
- 97 people
- Sponsor
- Astellas Pharma Europe B.V.
Lymphoma, Relapse
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
Because Primary Central Nervous System Lymphoma (PCNSL) are mainly diffuse large B-cell lymphoma of the activated B cells (ABC) type, the investigators hypothesize that the synergy of lenalidomide with rituximab shown in systemic…
- Trial name
- REVRI (NCT01956695)
- Testing
- Lenalidomide, Rituximab
- Where
- 12 sites in France
- Volunteers
- 45 people
- Sponsor
- Institut Curie
Leukemia
Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
RATIONALE: Biological therapies such as lenalidomide use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00096044
- Testing
- rituximab, lenalidomide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Roswell Park Cancer Institute
Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
This phase II trial studies the side effects and how well giving pegfilgrastim together with rituximab works in treating patients with untreated, relapsed, or refractory follicular lymphoma, small lymphocytic lymphoma (SLL), or…
- Conditions
- Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma
- Trial name
- NCT01682044
- Testing
- pegfilgrastim, rituximab, flow cytometry
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Immune Thrombocytopenic Purpura
Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this study is to compare the efficacy and…
- Trial name
- ITP (NCT01719692)
- Testing
- Rituximab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
This phase II clinical trial studies how well yttrium Y 90 ibritumomab tiuxetan, rituximab, and high-dose chemotherapy followed by peripheral blood stem cell transplant in treating patients with relapsed B-cell non-Hodgkin…
- Trial name
- NCT00695409
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- City of Hope Medical Center
Lymphoma, Large B-Cell, Diffuse
To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL
Part 1 (Phase Ib) Primary objective: To establish the maximum tolerated dose (MTD) of BI 836826 in combination with GemOx. Secondary objectives: To evaluate pharmacokinetics of BI 836826 when given in combination with GemOx and…
- Trial name
- NCT02624492
- Testing
- BI 836826, GemOx, Rituximab
- Where
- 7 sites in Belgium, Italy and 1 more
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Waldenstroms Macroglobulinemia
Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia
This is a Phase II multicenter study designed to evaluate the safety and efficacy of combination BDR. BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM.
- Trial name
- BDR-WM (NCT00832234)
- Testing
- Bortezomib, Dexamethasone, Rituximab
- Where
- Greece
- Volunteers
- 59 people
- Sponsor
- European Myeloma Network B.V.
Lymphoma, Non-Hodgkin, Child, Only
Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Objective: This study demonstrated that the efficacy and safety of intrathecal(IT) rituximab in the treatment of stage Ⅲ and Ⅳ non-Hodgkin lymphoma(NHL) in children.
- Trial name
- NCT06190457
- Testing
- intrathecal rituximab
- Volunteers
- 16 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lymphoma, Mantle Cell, Mantle Cell Lymphoma
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
This study will evaluate the effectiveness of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin-rituximab (EPOCH-R) chemotherapy plus bortezomib for treating mantle cell lymphoma, a cancer of white blood cells…
- Trial name
- NCT00114738
- Testing
- Rituximab (R), EPOCH, Bortezomib (B)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
This phase II trial studies how well a dose adjusted regimen consisting of etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (EPOCH) works in combination with ofatumumab or rituximab in…
- Conditions
- AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Trial name
- NCT02199184
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Dermatitis, Atopic
Immunopharmacological Effects of Rituximab in Atopic Dermatitis
Protocol Title: Immunopharmacological effects of Rituximab in atopic dermatitis Study Phase: Investigator driven study Study Design: Open-label, single center.
- Trial name
- NCT00267826
- Testing
- Rituximab
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- University of Bern
Opsoclonus-myoclonus Syndrome
Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome
The purpose of this study is to determine if cytokines, inflammatory mediators, are increased in spinal fluid and blood, correlate with disease activity, and could serve as biomarkers or therapeutic targets in children with…
- Trial name
- OMS (NCT00806182)
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Pediatric Neuroinflammation Organization, Inc.
Non-Hodgkin Lymphoma (NHL)
Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab
The purpose of this study is to compare the number of responders to vaccination with the influenza virus vaccine at different time points after last dose of rituximab in patients with lymphoma.
- Trial name
- Rituxivac (NCT01707628)
- Testing
- influenza vaccination with influenza vaccine
- Where
- 7 sites in Netherlands
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- St. Antonius Hospital
Lymphoma
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00007865
- Testing
- rituximab, carboplatin, etoposide
- Where
- United States
- Sponsor
- University of Nebraska
Mantle Cell Lymphoma
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
Eligible untreated patients will receive single arm venetoclax, bendamustine and rituximab as induction therapy. After 6 cycles, maintenance rituximab may be administered per physician discretion.
- Trial name
- PrE0405 (NCT03834688)
- Testing
- Venetoclax, Bendamustine, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- PrECOG, LLC.
B-Cell Malignancies
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, parsaclisib, as monotherapy and in combination…
- Trial name
- NCT02018861
- Testing
- Parsaclisib, Itacitinib, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 88 people
- Sponsor
- Incyte Corporation
Richter Syndrome
BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation
Blinatumomab (BLINCYTO) is a bi-specific T-cell engaging (BiTE®) antibody construct that transiently links CD3-positive T cells to CD19-positive B-cells, inducing T-cell activation and subsequent lysis of tumor cells.
- Trial name
- NCT03931642
- Testing
- RCHOP, Blinatumomab
- Where
- 28 sites in France
- Volunteers
- 41 people
- Sponsor
- French Innovative Leukemia Organisation
Non-hodgkin Lymphoma,B Cell
Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCCN guidelines for B cell lymphoma suggest that patients with relapsed/refractory aggressive NHL who are candidate for high-dose therapy should receive combination of cytotoxic chemotherapies as 2nd line treatment.
- Trial name
- NCT04094142
- Testing
- Acalabrutinib
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Seoul National University Hospital
Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
To investigate the tolerability and safety of OPB-111077 in combination with bendamustine and rituximab in patients with r/r DLBCL.
- Trial name
- NCT04049825
- Testing
- OPB-111077
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.